Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 6/2010

01.12.2010

Cytostatic Drugs, Neuregulin Activation of ErbB Receptors, and Angiogenesis

verfasst von: Nadia Hedhli, Kerry Strong Russell

Erschienen in: Current Hypertension Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Cytostatic drugs were developed to target specific molecular pathways shown to drive tumor growth. Although this approach has been very successful in treating cancers, its use is often hindered by off-target toxic effects. An example of this is trastuzumab, which targets the erbB2 kinase receptor. This drug successfully decreases tumor growth but adversely affects cardiac function. This observation led to important studies elucidating the importance of the erbB pathway in cardioprotection and angiogenesis. This review addresses the problem of off-target effects of cytostatic drugs (specifically trastuzumab) and their effect on cardiac function, summarizes the neuregulin-1 (NRG)/erbB signaling pathway, and discusses its importance in cardiac myocytes. It also highlights important findings showing the role of NRG/erbB signaling in microvascular preservation and angiogenesis, with a brief discussion of preclinical and clinical data regarding treatment of cardiovascular disease with NRG.
Literatur
1.
• Chen MH: Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep 2009, 11:167–174. This is a nice broad review of the cardiotoxicity of newer chemotherapeutic drugs.CrossRefPubMed
2.
Falls DL: Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003, 284:14–30.CrossRefPubMed
3.
Meyer D, Yamaai T, Garratt A, et al.: Isoform-specific expression and function of neuregulin. Development 1997, 124:3575–3586.PubMed
4.
Liu X, Gu X, Li Z, et al.: Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 2006, 48:1438–1447.CrossRefPubMed
5.
• Gao R, Zhang J, Cheng L, et al.: A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 2010, 55:1907–1914. This is the first published clinical trial of neuregulin in patients with heart failure.CrossRefPubMed
6.
Garrett TP, McKern NM, Lou M, et al.: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003, 11:495–505.CrossRefPubMed
7.
Lee K, Simon H, Chen H, et al.: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378:394–398.CrossRefPubMed
8.
Riese D, van Raaij T, Plowman G, et al.: The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 1995, 15:5770–5776.PubMed
9.
Zhao YY, Sawyer DR, Baliga RR, et al.: Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998, 273:10261–10269.CrossRefPubMed
10.
Rohrbach S, Niemann B, Silber RE Holtz, J: Neuregulin receptors erbB2 and erbB4 in failing human myocardium—depressed expression and attenuated activation. Basic Res Cardiol 2005, 100:240–249.CrossRefPubMed
11.
Russell KS, Stern DF, Polverini PJ, Bender JR: Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol 1999, 277:H2205–H2211.PubMed
12.
Cote GM, Miller TA, Lebrasseur NK, et al.: Neuregulin-1alpha and beta isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp Cell Res 2005, 311:135–146.CrossRefPubMed
13.
• Kalinowski A, Plowes NJ, Huang Q, et al.: Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells. FASEB J 2010, 24:2567–2575. The inflammatory cytokines IL-6 and IFNγ induce metalloproteinase-dependent cleavage of neuregulin from endothelial cells.CrossRefPubMed
14.
Uray IP, Connelly JH, Thomazy V, et al.: Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant 2002, 21:771–782.CrossRefPubMed
15.
• Ky B, Kimmel SE, Safa RN, et al.: Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 2009, 120:310–317. Increased NRG-1β in human serum is associated with heart failure, death, and cardiac transplantation, suggesting that NRG may be an important clinical biomarker.CrossRefPubMed
16.
Hintsanen M, Elovainio M, Puttonen S, et al.: Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men. Ann Behav Med 2007, 33:148–155.CrossRefPubMed
17.
Clement CM, Thomas LK, Mou Y, et al.: Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J Vasc Res 2007, 44:303–312.CrossRefPubMed
18.
• Xu G, Watanabe T, Iso Y, et al.: Preventive effects of heregulin-β1 on macrophage foam cell formation and atherosclerosis. Circ Res 2009, 105:500–510. NRG-1 inhibits atherogenesis and macrophage foam-cell formation via scavenger receptor class A (SR-A), acyl-coenzyme A:cholesterol acyltransferase (ACAT)1, and ATP-binding cassette transporter ABCA1.CrossRefPubMed
19.
Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783–792.CrossRefPubMed
20.
Baliga RR, Pimental DR, Zhao YY, et al.: NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am J Physiol 1999, 277:H2026–H2037.PubMed
21.
Lemmens K, Fransen P, Sys SU, et al.: Neuregulin-1 induces a negative inotropic effect in cardiac muscle: role of nitric oxide synthase. Circulation 2004, 109:324–326.CrossRefPubMed
22.
Fukazawa R, Miller TA, Kuramochi Y, et al.: Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 2003, 35:1473–1479.CrossRefPubMed
23.
Nakaoka Y, Nishida K, Narimatsu M, et al.: Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling. J Clin Invest 2007, 117:1771–1781.CrossRefPubMed
24.
• Horie T, Ono K, Nishi H, et al.: Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010, 87:656–664.CrossRefPubMed
25.
• Bersell K, Arab S, Haring B, Kuhn B: Neuregulin1/erbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 2009, 138:257–270. This was the first study to demonstrate that adult cardiac myocytes can proliferate in response to NRG.CrossRefPubMed
26.
Kuramochi Y, Cote GM, Guo X, et al.: Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem 2004, 279:51141–51147.CrossRefPubMed
27.
Huang Q, Kalinowski A, Palmeri M, et al.: Neuregulin decreases cardiac myocyte apoptosis induced by hypoxic injury [abstract]. Circulation 2005, 112(Suppl II):II-183.
28.
Timolati F, Ott D, Pentassuglia L, et al.: Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 2006, 41:845–854.CrossRefPubMed
29.
• Pentassuglia L, Graf M, Lane H, et al.: Inhibition of erbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 2009, 315:1302–1312. Inhibition of erbB2 in cardiac myocytes results in an inhibition of excitation contraction coupling and myofibrillar structural damage.CrossRefPubMed
30.
Grazette LP, Boecker W, Matsui T, et al.: Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for Herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004, 44:2231–2238.CrossRefPubMed
31.
Kuramochi Y, Guo X, Sawyer DB: Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006, 41:228–235.CrossRefPubMed
32.
Schneider JW, Chang AY, Garratt A: Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 2002, 29:22–28.PubMed
33.
Suter TM, Procter M, van Veldhuisen DJ, et al.: Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007, 25:3859–3865.CrossRefPubMed
34.
Brutsaert DL: Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003, 83:59–115.PubMed
35.
Li K, Rouleau JL, Andries LJ, Brutsaert DL: Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ Res 1993, 72:768–777.PubMed
36.
Rakusan K, Hrdina PW, Turek Z, et al.: Cell size and capillary supply of the hypertensive rat heart: quantitative study. Basic Res Cardiol 1984, 79:389–395.CrossRefPubMed
37.
Hudlicka O, Brown M, Egginton S: Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992, 72:369–417.PubMed
38.
Walsh K, Shiojima I: Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest 2007, 117:3176–3179.CrossRefPubMed
39.
Tirziu D, Chorianopoulos E, Moodie KL, et al.: Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest 2007, 117:3188–3197.CrossRefPubMed
40.
Shiojima I, Sato K, Izumiya Y, et al.: Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115:2108–2118.CrossRefPubMed
41.
• Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW: The cardiac microvasculature in hypertension, cardiac hypertrophy, and diastolic heart failure. Curr Vasc Pharmacol 2008, 6:292–300. This is a review of the importance of determining mechanisms to activate angiogenic genes in cardiac-related myopathies that are associated with capillary rarefaction.CrossRefPubMed
42.
• Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW: Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med 2008, 8:754–767. Loss of vascular repair in aging animals is associated with decreased hypoxia-inducible factor signaling and VEGF activation.CrossRefPubMed
43.
Houghton JL, Frank MJ, Carr AA, et al.: Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990, 15:43–51.CrossRefPubMed
44.
Debl K, Djavidani B, Buchner S, et al.: Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 2006, 92:1447–1451.CrossRefPubMed
45.
Hedhli N, Kalinowski A, Huang Q, et al.: Endothelial neuregulin expression is essential for maintaining capillaries in the heart and preserving cardiac function [abstract 3340]. Circulation 2009, 120:S791.
46.
Bagheri-Yarmand R, Vadlamudi RK, Wang RA, et al.: Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem 2000, 275:39451–39457.CrossRefPubMed
47.
Iivanainen E, Paatero I, Heikkinen SM, et al.: Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 2007, 313:2896–2909.CrossRefPubMed
48.
Panutsopulos D, Arvanitis DL, Tsatsanis C, et al.: Expression of heregulin in human coronary atherosclerotic lesions. J Vasc Res 2005, 42:463–474.CrossRefPubMed
49.
• Guler M, Yilmaz T, Ozercan I, Elkiran T: The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 2009, 147:703–708. Systemic administration of an erbB2 monoclonal antibody, trastuzumab, can decrease vascular formation.CrossRefPubMed
50.
Hedhli N, Dobrucki LW, Kalinowski A, et al.: Endothelial neuregulin expression is essential for angiogenesis in response to hindlimb ischemia [abstract 5111]. Circulation 2009, 120:S1052.
Metadaten
Titel
Cytostatic Drugs, Neuregulin Activation of ErbB Receptors, and Angiogenesis
verfasst von
Nadia Hedhli
Kerry Strong Russell
Publikationsdatum
01.12.2010
Verlag
Current Science Inc.
Erschienen in
Current Hypertension Reports / Ausgabe 6/2010
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0148-9

Weitere Artikel der Ausgabe 6/2010

Current Hypertension Reports 6/2010 Zur Ausgabe

ReviewPaper

Diagnosis and Treatment of Hypertension in Children

ReviewPaper

Are There Benefits of Antihypertensive Therapy Beyond Blood Pressure Lowering?

ReviewPaper

Vascular Endothelial Function and Hypertension: Insights and Directions

ReviewPaper

Establishing Targets for Hypertension Control in Patients with Comorbidities

ReviewPaper

Genetic Testing for Pheochromocytoma

Clinical Trial Report

Insulin Sensitizers and Heart Failure: An Engine Flooded with Fuel

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise